University Hospital St Marina Varna

At University Hospital St Marina Varna, research in oncology and hematology focuses on cancers and blood disorders such as non-small cell lung cancer, diffuse large B-cell lymphoma, chronic myeloid leukemia, and myelodysplastic syndromes. These studies are designed to test new treatment options, improve disease control, and evaluate whether targeted and immune-based therapies can offer better outcomes for patients with advanced or hard-to-treat disease.

• Non-small cell lung cancer and HER2-mutated lung cancer are being studied to assess new anticancer approaches.
• Diffuse large B-cell lymphoma trials aim to improve outcomes in relapsed or refractory disease.
• Chronic myeloid leukemia, myelofibrosis, and myelodysplastic syndromes research is focused on treatment effectiveness and tolerability.
• Immune thrombocytopenia and anemia related to marrow disorders are included to explore better blood-disease management.

Overall, the site is active in evaluating targeted therapies, combination regimens, and supportive approaches that may improve survival and quality of life in patients with complex blood cancers.

Clinical trials in cardiology at this site address major conditions such as heart failure, atherosclerotic cardiovascular disease, acute myocardial infarction, and hypercholesterolemia. The research is centered on testing new therapies that may reduce cardiovascular events, lower inflammation, and improve long-term heart health in patients with high-risk disease.

• Heart failure studies are evaluating treatments for symptomatic patients with reduced or preserved heart function.
• Acute myocardial infarction research is exploring ways to reduce the risk of future major cardiac events.
• Atherosclerotic cardiovascular disease and systemic inflammation are being investigated to better prevent complications.
• Hypercholesterolemia trials focus on improving lipid control and cardiovascular risk reduction.

These studies reflect a strong interest in prevention, risk reduction, and more effective management of chronic cardiovascular conditions.

In gastroenterology, the research portfolio includes Crohn’s disease and ulcerative colitis, two major forms of inflammatory bowel disease. The trials are intended to assess whether new treatments can better control inflammation, improve symptoms, and support patients who have not responded well to standard care.

• Moderate to severe Crohn’s disease studies are looking at better control of bowel inflammation and disease activity.
• Ulcerative colitis research is evaluating safety and effectiveness of newer anti-inflammatory therapies.
• These trials aim to improve symptom relief and long-term disease management.

The work in this area highlights the site’s role in advancing more effective treatment options for chronic digestive disorders.

Research in infectious diseases includes studies of complicated urinary tract infection and acute pyelonephritis. The goal is to compare new oral and established antibiotic treatments to see whether they can provide effective infection control while supporting recovery in hospitalized adults.

• Complicated urinary tract infection studies are focused on treatment effectiveness and clinical cure.
• Acute pyelonephritis trials examine better options for serious kidney-related infection.
• These investigations support efforts to improve antibiotic care and patient outcomes in acute bacterial infections.

This area shows interest in practical, patient-centered approaches to managing serious infections more effectively.

The hematology program also includes trials in myelofibrosis and immune thrombocytopenia, with a focus on reducing symptoms, improving blood counts, and supporting patients whose disease remains difficult to manage. Researchers are also examining therapies for transfusion-dependent anemia linked to marrow disorders.

• Primary myelofibrosis and related post-disease forms are being studied for symptom relief and spleen size reduction.
• Immune thrombocytopenia trials aim to improve platelet response and treatment durability.
• Myelodysplastic syndromes research is centered on reducing the need for red blood cell transfusions.

At University Hospital St Marina Varna, this field reflects ongoing efforts to refine care for chronic blood disorders through more targeted and better-tolerated therapies.